| (USD) | Sep 2023 | Q/Q |
|---|---|---|
| Revenue | 126.4MM | +6% |
| Gross Profit | 111.9MM | +6% |
| Cost Of Revenue | 14.5MM | +5% |
| Operating Income | 2.1MM | -240% |
| Operating Expenses | 109.8MM | +3% |
| Net Income | 3.2MM | +52% |
| R&D | 21.5MM | +2% |
| G&A | 88.3MM | +3% |
| Interest Expense | 43K | -2% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
IRVINE, Calif., April 17, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today announced that it will release its first quarter 2024 financial results on Tuesday, April 30, 2024. In conjunction with the release, Inari will host a conference call and webcast at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and rec
IRVINE, Calif., April 11, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today announced the publication of its 2023 Ethos and Sustainability Report. The report highlights Inari’s commitment to its ethos and important corresponding environmental, social and governance (ESG) initiatives. The report can be found on Inari’s website here. “We are prou
Inari Medical (NARI) continues to gain from its expanded product portfolio. However, continued loss at the operating level raises concern.
IRVINE, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), today announced the appointment of Tim Benner as Senior Vice President of U.S. Sales and Dr. Andrew Niekamp as Vice President of Medical Affairs. Mr. Benner will be responsible for developing effective strategies across the company's multi-product sales platform and leading a high-performance commercial team to drive therapy penetration. Dr. Niekamp will be instrumental in advancing Inari’s mission t
Inari Medical (NARI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
AppFolio Inc. (NASD:APPF) will replace Inari Medical Inc. (NASD:NARI) in the S&P MidCap 400, and Inari Medical will replace Callon Petroleum Co. (NYSE:CPE) in the S&P SmallCap 600 effective prior to the opening of trading on Monday, April 1. S&P 500 constituent APA Corp. (NASD:APA) is acquiring Callon Petroleum in a transaction expected to be completed on or about that date pending final conditions.
In a recent transaction filed with the SEC, Director William Hoffman sold 40,000 shares of Inari Medical Inc (NASDAQ:NARI) on March 18, 2024.
Inari Medical (NARI) announces two-year interim results from the CLOUT registry, which shows a significant improvement in patient's post-thrombotic syndrome and lower rethrombosis-related events.
Rates of Post Thrombotic Syndrome at two years were excellent and significantly lower than rates reported in historical Deep Vein Thrombosis trialsIRVINE, Calif., March 12, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”) a medical device company focused on developing products to treat and transform the lives of patients suffering from venous and other diseases, announced positive two-year interim results from the CLOUT registry. The data was presented at the American Venous
Inari Medical (NARI) continues to benefit from its commitment to understanding the venous system. However, its dependency on the adoption of products is a concern.